| Category |
Cell Line |
Product ID |
Profiling |
Screening |
CryoRedi |
| Oncology |
|
|
|
|
|
| AFX, Fox04 (New) |
USOS |
090_01 |
 |
|
|
| Akt1 |
CHO |
085_01 |
|
|
|
| Akt1-PH |
CHO |
006_01 |
|
|
|
| Akt2 |
CHO |
011_02 |
|
|
|
| Akt3 |
CHO |
012_01 |
|
|
|
| Btk-PH |
CHO |
007_01 |
|
|
|
| Forkhead, FOXO1A |
U2OS |
008_01 |
|
|
|
| Forkhead L1, FOXO3A |
U2OS |
009_02 |
|
|
|
| EGFR (New) |
U2OS |
082_01 |
|
|
| ERF, MAPK pathway reporter |
T24 |
019_01 |
|
|
|
| ERF, MAPK pathway reporter |
U2OS |
022_01 |
|
|
|
| Hexokinase 2 |
U2OS |
050_01 |
|
|
|
| Hif-1α |
U2OS |
066_02 |
|
|
|
| PDK1 |
CHO |
013_01 |
|
|
|
| Ras activation |
CHO |
049_01 |
|
|
|
| Rac1 activation |
CHO |
068_01 |
|
|
|
| HIF -1α |
CHO |
066_01 |
|
|
|
|
| Inflammation |
|
|
|
|
|
| 5-lipoxygenase |
(CHO) |
083_01 |
|
|
|
| ERF, MAPK pathway reporter |
T24 |
019_01 |
|
|
|
| ERF, MAPK pathway reporter |
U2OS |
022_01 |
|
|
|
| ERK2 |
U2OS |
083_01 |
|
|
|
| MAPKAPK2, MK2 (IL 1β or TNFα activated) |
U2OS |
037_01 |
|
|
|
| MK2EE, constitutively active |
U2OS |
038_01 |
|
|
|
| NFATc1 |
U2OS |
017_01 |
|
|
|
| NFkB p65 (New) |
USOS |
091_01 |
|
|
|
|
| STAT1 |
U2OS |
035_01 |
|
|
|
| STAT3, EGF stimulated |
MDA-MB-468 |
016_01 |
|
|
|
| STAT3, IL-6 stimulated |
U2OS |
015_01 |
|
|
|
|
| GPCR Internalization Assays |
|
|
|
|
|
| Cannabinoid receptor CB1, agonist and antagonist |
U2OS |
051_01 |
|
|
|
| Cannabinoid receptor CB2, agonist and antagonist |
U2OS |
061_01 |
|
|
|
| CRTH2 (New) |
U2OS |
093_01 |
|
|
|
| CXCR4, agonist and antagonist |
U2OS |
018_01 |
|
|
|
| FSHR |
U2OS |
053_01 |
|
|
|
| GRPR (New) |
U2OS |
094_01 |
|
|
|
| Melanin concentrating hormone receptor MCH1, agonist |
U2OS |
054_01 |
|
|
|
| Melanocortin receptor MC4, agonist and antagonist |
U2OS |
057_01 |
|
|
|
| S1P3 (New) |
U2OS |
095_01 |
|
|
|
| S1P1 (EDG1), agonist and antagonist |
U2OS |
039_01 |
|
|
|
| Angiotensin II type 1 receptor (AT1R) |
U2OS |
071_01 |
|
|
|
| Mu (μ)-Opioid receptor 1 (MOR1) |
U2OS |
070_01 |
|
|
|
| Muscarinic receptor 1 (M1) (New) |
U2OS |
086_01 |
|
|
| Muscarinic receptor 2 (M2) |
U2OS |
075_01 |
|
|
|
| Muscarinic receptor 3 (M3) |
U2OS |
076_01 |
|
|
|
|
| GPCR Activation Reporter Cell Lines |
|
|
|
|
|
Gs-coupled GPCRs - Protein
Kinase A |
CHO-K1 |
045_02 |
|
|
|
| Gq-coupled GPCRs - NFATc1 |
U2OS |
017_02 |
|
|
|
|
| GPCR Activation Assays |
|
|
|
|
|
| NK1: NFATc1 |
U2OS |
048_01 |
|
|
|
| β2-AR: PKA |
CHO-K1 |
046_01 |
|
|
|
| GlucagonR: PKA |
CHO-K1 |
047_01 |
|
|
|
| S1P 1: PKA |
CHO-K1 |
067_01 |
|
|
|
| M1:NFATc1 |
U2OS |
088_01 |
|
|
|
| M2:PKA |
CHO-K1 |
072_01 |
|
|
|
| M3:NFATc1 |
U2OS |
073_01 |
|
|
|
| MOR1:PKA (New) |
CHO |
081_01 |
|
|
|
| MCHR1:NFATc1 |
U2OS |
079_01 |
|
|
|
| AT1R:NFATc1 |
U2OS |
078_01 |
|
|
|
| |
| Metabolic Disease |
|
|
|
|
|
| GLUT1, agonist and antagonist (New) |
CHO |
089_01 |
|
|
|
| GLUT4, agonist and antagonist |
CHO |
023_01 |
|
|
|
| TULP-3, agonist |
U2OS |
059_01 |
|
|
|
| TORC2 |
U2OS |
065_01 |
|
|
|
| HDAC5 |
SW480 |
069_01 |
|
|
|
|
| Nuclear Hormone Receptors |
|
|
|
|
|
| Androgen receptor |
U2OS |
043_01 |
|
|
|
Estrogen receptor α, agonist and antagonist
|
U2OS |
056_01 |
|
|
|
Estrogen receptor β, agonist and antagonist |
U2OS |
063_01 |
|
|
|
| Glucocorticoid Receptor |
U2OS |
014_01 |
|
|
|
| Vitamin D receptor |
U2OS |
060_01 |
|
|
|
| Progesterone Receptor |
U2OS |
064_01 |
|
|
|
| Pregnane X Receptor (PXR) |
U2OS |
077_01 |
|
|
|
|
| Cell Toxicity |
|
|
|
|
|
| Rad51 (DNA damage) |
SW480 |
042_01 |
|
|
|
| ATF6 (ER stress) |
U2OS |
084_01 |
|
|
|
|
| Wnt Pathway |
|
|
|
|
|
| β-Catenin |
U2OS |
040_01 |
|
|
|
|
| TGF-β Pathway |
|
|
|
|
|
| Smad2 |
MDA-468 |
044_01 |
|
|
|
|
| Phosphodiesterases |
|
|
|
|
|
| PDE4A4 |
CHO |
029_01 |
|
|
|
|
| Protein Degradation |
|
|
|
|
|
| Proteasome, UBi(G76V)-GFP |
U2OS |
021_02 |
|
|
|
| SCF-Skp2 E3 ligase:p27 |
HeLa |
052_01 |
|
|
|
| E6-AP E3 ligase:p53 |
HeLa |
055_01 |
|
|
|
|
| Nuclear Export |
|
|
|
|
|
| Rev, nuclear export |
U2OS |
062_01 |
|
|
|
| Rev, nuclear export |
BHK |
010_02 |
|
|
|
|
| Protein Kinases |
|
|
|
|
|
| Protein Kinase A |
CHO-K1 |
045_01 |
|
|
|
|
| Protein-Protein
Interactions |
|
|
|
|
|
| p53-HDM2, GRIP technology |
CHO |
020_01 |
|
|
|
|
| Membrane Trafficking |
|
|
|
|
|
| FYVE domain |
U2OS |
074_01 |
|
|
|
|
| Coming
Soon |
|
|
|
|
|
|
| Assays
currently in development typically require
3-6 months lead time for full validation
and screening configuration.
For further information on the BioImage Redistribution® assays, please contact us at:
The trademarks BioImage and Redistribution used herein are owned by Fisher BioImage ApS, Denmark; BioImage is part of Thermo Fisher Scientific. |
